Growth Differentiation Factor-15 in Diabetic Kidney and Cardiovascular Disease: Pathogenic Driver or Protective...

Area of Science:

• Metabolic and cardiovascular research
• Biomarker discovery
• Molecular mechanisms of disease

Background:

• Diabetic kidney disease (DKD) and diabetic cardiomyopathy significantly increase morbidity and mortality in diabetes.
• Growth differentiation factor-15 (GDF-15), a stress-inducible cytokine, is a recognized biomarker and potential modulator of metabolic inflammation.
• The precise role of GDF-15 in disease progression remains debated: is it merely an indicator of distress or an active participant in disease pathogenesis?

Purpose of the Study:

• To explore the dual role of GDF-15 in signaling and shaping diabetic kidney disease and cardiovascular disease.
• To elucidate the context-dependent biology of GDF-15, differentiating its protective versus pathogenic effects in diabetes.
• To investigate the regulatory mechanisms and clinical implications of GDF-15 in metabolic diseases.

Main Methods:

• Review of experimental models, longitudinal clinical studies, and multi-omics analyses.
• Examination of GDF-15 regulation via the GFRAL-RET signaling axis.
• Analysis of GDF-15 expression across renal tubular compartments and its role in cardiac remodeling.

Main Results:

• GDF-15 exhibits context-dependent effects, being protective during acute stress but potentially pathogenic with chronic elevation in diabetes.
• Elevated circulating GDF-15 serves as an early, sensitive indicator of DKD progression and cardiovascular events.
• Sustained GDF-15 signaling is increasingly implicated in mitochondrial dysfunction, inflammatory amplification, and maladaptive tissue remodeling.

Conclusions:

• GDF-15 is at a critical juncture, serving as both a risk stratification biomarker and a mechanistic player in diabetes complications.
• Defining the precise conditions under which GDF-15 signaling is adaptive versus maladaptive is crucial for therapeutic development.
• Future strategies may involve targeting, harnessing, or restraining GDF-15 signaling for managing diabetes-related complications.